Summary

Delian Asparouhov of Varda joins to discuss the shift from theoretical orbital experiments to revenue-generating manufacturing in space. While tech giants chase orbital data centers, Varda is securing multi-year pharmaceutical contracts, prioritizing durable manufacturing economics over speculative infrastructure.

Key Topics

• Microgravity Phase-Change Manufacturing: In normal gravity, liquids separate as they solidify, creating imperfections. By removing gravity during the phase-change from liquid to solid, Varda creates purer, more effective pharmaceutical crystals that can be turned into easier-to-administer medicine.
• Sun-Synchronous Orbit (SSO): SSO is the standard for most imaging satellites because it keeps lighting conditions consistent. While Varda often uses it, they are increasingly seeking orbital flexibility to optimize launch costs and avoid orbital traffic.
• Blockbuster Drug Economics: In space manufacturing, high-value drugs (like oncology treatments) provide the economic foundation to pay for space flight, as the mass of the core ingredient required is small compared to its multi-billion dollar market value.

Key Takeaways

• Monitor Varda's 2026/2027 flight cadence.
• Review your firm's AI integration strategy.